|
|
|
|
| LEADER |
04976nam a22004815i 4500 |
| 001 |
978-3-030-32459-9 |
| 003 |
DE-He213 |
| 005 |
20210622175140.0 |
| 007 |
cr nn 008mamaa |
| 008 |
191126s2019 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783030324599
|9 978-3-030-32459-9
|
| 024 |
7 |
|
|a 10.1007/978-3-030-32459-9
|2 doi
|
| 050 |
|
4 |
|a RM281
|
| 050 |
|
4 |
|a QR189-189.5
|
| 072 |
|
7 |
|a MJCM
|2 bicssc
|
| 072 |
|
7 |
|a MED044000
|2 bisacsh
|
| 072 |
|
7 |
|a MJCM
|2 thema
|
| 082 |
0 |
4 |
|a 615.372
|2 23
|
| 100 |
1 |
|
|a Van Regenmortel, Marc H V.
|e author.
|4 aut
|4 http://id.loc.gov/vocabulary/relators/aut
|
| 245 |
1 |
0 |
|a HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design
|h [electronic resource] :
|b A Review of 20 Years of Research /
|c by Marc H V Van Regenmortel.
|
| 250 |
|
|
|a 1st ed. 2019.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2019.
|
| 300 |
|
|
|a XXVII, 364 p. 20 illus., 12 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 505 |
0 |
|
|a Part I.Immunochemistry -- 1 What is a B cell epitope -- 2 Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure–function relationships in immunology -- 3 Synthetic Peptide Vaccines and the Search for Neutralization B Cell Epitopes -- 4 Specificity, polyspecificity, and heterospecificity of antibody‐antigen recognition -- Part II. Reductionism -- 5 Reductionism and the search for structure–function relationships in antibody molecules -- 6 Reductionism and complexity in molecular biology -- 7 Editorial: Biological complexity emerges from the ashes of genetic reductionism -- 8 The rational design of biological complexity: A deceptive metaphor., 9 Basic research in HIV vaccinology is hampered by reductionist thinking -- 10 Commentary: Basic Research in HIV Vaccinology Is Hampered by Reductionist Thinking -- 11 Nature and Consequences of Biological Reductionism for the Immunological Study of Infectious Diseases., Part III. Vaccinology -- 12 Limitations to the structure‐based design of HIV‐1 vaccine immunogens -- 13 Two meanings of reverse vaccinology and the empirical nature of vaccine science -- 14 Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine -- 15 Paradigm Changes and the Future of HIV Vaccine Research: A Summary of a Workshop Held in Baltimore on 20 November 2013 -- 16 Editorial: Paradigm changes are required in HIV vaccine research -- 17 An outdated notion of antibody specificity is one of the major detrimental assumptions of the structure-based reverse vaccinology paradigm, which prevented it from helping to develop an effective HIV-1 vaccine -- 18 More surprises in the development of an HIV vaccine -- 19 Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 not Inform the Rational Design of an HIV-1 Vaccine? -- 20 Old and New Concepts and Strategies in HIV Vaccinology: A Report from a Workshop held in Rome on 17 June 2016 -- 21 Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory -- 22 Immune systems rather than antigenic epitopes elicit and produce protective antibodies against HIV -- 23 Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which Is Unattainable by Rational Vaccine Design -- 24 Viral species, viral genomes and HIV vaccine design: is the rational design of biological complexity a utopia?
|
| 520 |
|
|
|a This book gathers a series of pivotal papers on the development of an HIV/AIDS vaccine published in the last two decades. Accompanied by extensive comments putting the material into an up-to-date context, all three parts of the book offer a broad overview of the numerous unsuccessful attempts made in recent years to develop a preventive HIV vaccine. Providing a detailed review and analysis of studies published from 1998 to the present day, it examines the likely reasons for the failure to develop an HIV vaccine despite multi-million dollar investments.
|
| 650 |
|
0 |
|a Vaccines.
|
| 650 |
|
0 |
|a Virology.
|
| 650 |
1 |
4 |
|a Vaccine.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/B16010
|
| 650 |
2 |
4 |
|a Virology.
|0 https://scigraph.springernature.com/ontologies/product-market-codes/B22003
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer Nature eBook
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783030324582
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783030324605
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783030324612
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-030-32459-9
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 912 |
|
|
|a ZDB-2-SXB
|
| 950 |
|
|
|a Biomedical and Life Sciences (SpringerNature-11642)
|
| 950 |
|
|
|a Biomedical and Life Sciences (R0) (SpringerNature-43708)
|
